CBUS
Cibus, Inc.
CBUS has the edge over NVO overall, supported by stronger modeled upside and stronger fundamentals.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
CBUS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
CBUS's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CBUS PE Valuation
CBUS has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
CBUS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect CBUS's revenue to grow, with its earnings and profitability holding steady.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CBUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.30 | +$2.03 |
| Q2 2026 | -$1.45 | +$9.07 |
| Q1 2026 | -$1.77 | +$9.28 |
| Q4 2025 | -$2.78 | +$8.05 |
| Q3 2025 | -$3.33 | +$26.78 |
| Q2 2025 | -$10.52 | +$13.55 |
| Q1 2025 | -$11.05 | +$14.93 |
| Q4 2024 | -$10.83 | +$19.48 |
CBUS is still losing money, but far less than before: $1.30 per share over the past year, against $68.00 at its worst in mid-2020.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CBUS on earnings quality, reporting a profit while its opponent remains loss making.
CBUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $800K | +30% |
| Q2 2026 | $994K | +6.5% |
| Q1 2026 | $1.7M | +63% |
| Q4 2025 | $1.1M | -13% |
| Q3 2025 | $615K | -63% |
| Q2 2025 | $933K | +11% |
| Q1 2025 | $1M | +90% |
| Q4 2024 | $1.2M | +9.9% |
CBUS's revenue is recovering but still below its 2020 peak: $800,000 last quarter, up 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1563% | +947 points |
| Q2 2026 | -1300% | +623 points |
| Q1 2026 | -721% | +3299 points |
| Q4 2025 | -2136% | -649 points |
| Q3 2025 | -2510% | +9514 points |
| Q2 2025 | -1923% | +640 points |
| Q1 2025 | -4020% | -635 points |
| Q4 2024 | -1487% | +22929 points |
CBUS's operating margin was −1563% last quarter, up 947 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over CBUS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CBUS on profitability, with a higher operating margin.
CBUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.3M | +$2.5M |
| Q2 2026 | -$9.4M | +$4.3M |
| Q1 2026 | -$11.6M | +$517K |
| Q4 2025 | -$13.5M | +$545K |
| Q3 2025 | -$11.8M | +$2M |
| Q2 2025 | -$13.7M | +$3.5M |
| Q1 2025 | -$12.1M | +$1.6M |
| Q4 2024 | -$14.1M | +$3.4M |
CBUS has burned cash in almost every quarter: −$44M over the past year, against −$52M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over CBUS on cash generation, producing positive trailing cash flow while its opponent burns cash.
CBUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +137K shares |
| 1 year | +45% | +24M shares |
| 3 years | +7682% | +75.9M shares |
| 5 years | +10253% | +76.2M shares |
| Available history | +11620% | +76.2M shares |
CBUS has 77M diluted shares, up 45% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CBUS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CBUS Net Leverage
CBUS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
CBUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 4.7 | Oversold |
CBUS's weekly RSI is 38 (neutral) and its Stochastic is 5 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CBUS PE vs Healthcare Sector
CBUS has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CBUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.38 | 21% below |
| 20 week MA | $1.58 | 31% below |
| 50 week MA | $1.77 | 38% below |
| 100 week MA | $1.82 | 40% below |
| 200 week MA | $8.07 | 86% below |
CBUS is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over CBUS on trend strength, trading above more of its moving averages.
CBUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $320.5 | $215.5 | -33% |
| 2021 | $215.5 | $111.5 | -48% |
| 2022 | $111.5 | $6.60 | -94% |
| 2023 | $6.60 | $19.6 | +198% |
| 2024 | $19.6 | $2.36 | -88% |
| 2025 | $2.36 | $1.70 | -28% |
| 2026 YTD | $1.70 | $1.09 | -36% |
CBUS's yearly returns have swung widely, from +198% in 2023 to −94% in 2022. It's down 36% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over CBUS on returns for 2026, with the stronger performance.